Polymorphisms in miRNA processing genes and their role in osteosarcoma risk

Bilbao-Aldaiturriaga, Nerea; Gutiérrez-Camino, Ángela; Martín-Guerrero, Idoia; Pombar-Gomez, Maria; Zalacain-Díez, Marta; López-López, Elixabet; Garcı́a-Orad, Africa

doi:10.1002/pbc.25416

Cited by 15 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite recent advancements in multimodal treatments (e.g., wide tumor excision, adjuvant chemotherapy, and radiotherapy), survival expectancies have not improved much over the past 25 years (Kager et al, 2003), especially for patients with metastasis and recurrent osteosarcoma. Previous studies have provided some clues to the molecular pathogenesis of osteosarcoma (Bilbao-Aldaiturriaga et al, 2015;Chen et al, 2015;Sun et al, 2015a;Yuan et al, 2015;Zhao et al, 2015). However, the exact mechanisms underlying its formation and progression are still obscure and further identification of new candidate molecules participating in these processes is important for improving the diagnosis, prevention, and treatment of this disease.…”

Section: Introductionmentioning

confidence: 99%

Increased expression of the lncRNA BANCR and its prognostic significance in human osteosarcoma

Zq¹,

R-B²,

Dm³

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Long noncoding RNAs (lncRNAs) play important roles in the formation and progression of many types of human malignancies. The aim of our study was to investigate the expression and biological functions of the lncRNA BRAF-activated noncoding RNA (BANCR) in human osteosarcoma. BANCR expression was quantified by real-time PCR in human osteosarcoma cell lines and tissues. We analyzed the association between BANCR levels and clinicopathological factors and patient prognosis. MTT, flow cytometric, and transwell invasion assays were performed to observe the effects of BANCR on MG-63 cell biological behaviors. BANCR overexpression was observed in osteosarcoma cell lines and clinical specimens. Increased BANCR expression was significantly associated with large tumor size, positive distant metastasis, and advanced clinical stage. High BANCR expression in osteosarcoma was an independent predictor of poor survival. Downregulation of BANCR inhibited MG-63 cell proliferation and invasion and promoted cell apoptosis in vitro. These findings suggested that BANCR may act as a tumor promoter in osteosarcoma and could serve as a potential therapeutic target for this disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Increased expression of the lncRNA BANCR and its prognostic significance in human osteosarcoma

Zq¹,

R-B²,

Dm³

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…MiRs are thought to influence cell proliferation, apoptosis, chemo-and radiation-sensitivity, and metastasis in cancers and could even potentially define the phenotype of cancer stem cells (Esquela-Kerscher and Slack, 2006;Fang et al, 2015;Garofalo and Croce, 2015;Yang et al, 2015). Recently, reports of the correlation between dysregulated miRs and osteosarcoma initiation and progression are increasing, providing new insights for osteosarcoma treatment (Bilbao-Aldaiturriaga et al, 2015;Sun et al, 2015;Zhang et al, 2015;Zhao et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Decreased expression of tumor suppressive miR-874 and its clinical significance in human osteosarcoma

Zhang¹,

Sun²,

Li³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Dysregulation of microRNAs (miRs) is associated with cancer development and progression and aberrant expression of miR-874 have been found in some types of cancer. However, the expression and function of miR-874 in osteosarcoma remain unclear. The aim of this study was to explore the effects of miR-874 in osteosarcoma tumorigenesis and development. The expression level of miR-874 was quantified by real-time reverse transcription-polymerase chain reaction (RT-PCR) in human osteosarcoma cell lines and tissues. Using a miR-874 mimic, cell proliferation and migration assays were performed in an osteosarcoma cell line and tumorigenicity was observed in vivo in order to determine the effects of miR-874 in osteosarcoma cell lines and tissues. MiR-874 was significantly downregulated in osteosarcoma cell lines and clinical (2015) specimens. Decreased miR-874 expression was significantly associated with large tumor size, distant metastasis, and advanced clinical stage, and was an independent predictor of poor survival. Overexpression of miR-874 inhibited cell proliferation, invasion and migration in vitro, promoted cell apoptosis in vitro, and suppressed tumorigenicity in vivo. These findings indicate that miR-874 may act as a tumor suppressor in osteosarcoma and could serve as a novel therapeutic agent for miRbased therapy.

show abstract

“…Among non-coding elements, those that have been most extensively studied in HGOS are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Although some evidence of the possible involvement of non-coding RNAs in HGOS pathogenesis has been reported [ 132 , 133 , 134 , 135 ], very few data have been provided so far regarding the potential impact of polymorphisms affecting miRNAs or lncRNAs on HGOS survival.…”

Section: Polymorphisms Of Non-coding Rnasmentioning

confidence: 99%

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Hattinger

Patrizio

Luppi

et al. 2020

IJMS

View full text Add to dashboard Cite

High-grade osteosarcoma (HGOS) is a very aggressive bone tumor which primarily affects adolescents and young adults. Although not advanced as is the case for other cancers, pharmacogenetic and pharmacogenomic studies applied to HGOS have been providing hope for an improved understanding of the biology and the identification of genetic biomarkers, which may impact on clinical care management. Recent developments of pharmacogenetics and pharmacogenomics in HGOS are expected to: i) highlight genetic events that trigger oncogenesis or which may act as drivers of disease; ii) validate research models that best predict clinical behavior; and iii) indicate genetic biomarkers associated with clinical outcome (in terms of treatment response, survival probability and susceptibility to chemotherapy-related toxicities). The generated body of information may be translated to clinical settings, in order to improve both effectiveness and safety of conventional chemotherapy trials as well as to indicate new tailored treatment strategies. Here, we review and summarize the current scientific evidence for each of the aforementioned issues in view of possible clinical applications.

show abstract

Polymorphisms in miRNA processing genes and their role in osteosarcoma risk

Abstract: This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1.

Cited by 15 publications

References 42 publications

Increased expression of the lncRNA BANCR and its prognostic significance in human osteosarcoma

Increased expression of the lncRNA BANCR and its prognostic significance in human osteosarcoma

Decreased expression of tumor suppressive miR-874 and its clinical significance in human osteosarcoma

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Contact Info

Product

Resources

About